222 related articles for article (PubMed ID: 32098059)
21. SOX9 expression increases with malignant potential in tumors from patients with neurofibromatosis 1 and is not correlated to desert hedgehog.
Carbonnelle-Puscian A; Vidal V; Laurendeau I; Valeyrie-Allanore L; Vidaud D; Bièche I; Leroy K; Lantieri L; Wolkenstein P; Schedl A; Ortonne N
Hum Pathol; 2011 Mar; 42(3):434-43. PubMed ID: 21193222
[TBL] [Abstract][Full Text] [Related]
22. High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization.
Mantripragada KK; Spurlock G; Kluwe L; Chuzhanova N; Ferner RE; Frayling IM; Dumanski JP; Guha A; Mautner V; Upadhyaya M
Clin Cancer Res; 2008 Feb; 14(4):1015-24. PubMed ID: 18281533
[TBL] [Abstract][Full Text] [Related]
23. Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas.
Pemov A; Hansen NF; Sindiri S; Patidar R; Higham CS; Dombi E; Miettinen MM; Fetsch P; Brems H; Chandrasekharappa SC; Jones K; Zhu B; Wei JS; ; ; Mullikin JC; Wallace MR; Khan J; Legius E; Widemann BC; Stewart DR
Neuro Oncol; 2019 Aug; 21(8):981-992. PubMed ID: 30722027
[TBL] [Abstract][Full Text] [Related]
24. Identification of potential common genetic modifiers of neurofibromas: a genome-wide association study in 1333 patients with neurofibromatosis type 1.
Pacot L; Sabbagh A; Sohier P; Hadjadj D; Ye M; Boland-Auge A; Bacq-Daian D; Laurendeau I; Briand-Suleau A; Deleuze JF; Margueron R; Vidaud M; Ferkal S; Parfait B; Vidaud D; ; Pasmant E; Wolkenstein P
Br J Dermatol; 2024 Jan; 190(2):226-243. PubMed ID: 37831592
[TBL] [Abstract][Full Text] [Related]
25. Association of plexiform and diffuse neurofibromas with malignant peripheral nerve sheath tumor in NF I patients: a whole-body MRI assessment.
Attia S; Guirguis M; Le LQ; Chhabra A
Skeletal Radiol; 2024 Apr; 53(4):769-777. PubMed ID: 37903998
[TBL] [Abstract][Full Text] [Related]
26. Recent advances in neurofibromatosis type 1.
Arun D; Gutmann DH
Curr Opin Neurol; 2004 Apr; 17(2):101-5. PubMed ID: 15021234
[TBL] [Abstract][Full Text] [Related]
27. Characterization of the somatic mutational spectrum of the neurofibromatosis type 1 (NF1) gene in neurofibromatosis patients with benign and malignant tumors.
Upadhyaya M; Han S; Consoli C; Majounie E; Horan M; Thomas NS; Potts C; Griffiths S; Ruggieri M; von Deimling A; Cooper DN
Hum Mutat; 2004 Feb; 23(2):134-146. PubMed ID: 14722917
[TBL] [Abstract][Full Text] [Related]
28. Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis.
Upadhyaya M; Spurlock G; Thomas L; Thomas NS; Richards M; Mautner VF; Cooper DN; Guha A; Yan J
Hum Mutat; 2012 Apr; 33(4):763-76. PubMed ID: 22331697
[TBL] [Abstract][Full Text] [Related]
29. Differentially expressed genes in neurofibromatosis 1-associated neurofibromas and malignant peripheral nerve sheath tumors.
Holtkamp N; Mautner VF; Friedrich RE; Harder A; Hartmann C; Theallier-Janko A; Hoffmann KT; von Deimling A
Acta Neuropathol; 2004 Feb; 107(2):159-68. PubMed ID: 14673600
[TBL] [Abstract][Full Text] [Related]
30. NF1 mutations in neurofibromatosis 1 patients with plexiform neurofibromas.
Kluwe L; Friedrich RE; Korf B; Fahsold R; Mautner VF
Hum Mutat; 2002 Mar; 19(3):309. PubMed ID: 11857752
[TBL] [Abstract][Full Text] [Related]
31. Adhesion molecule L1 is down-regulated in malignant peripheral nerve sheath tumors versus benign neurofibromatosis type 1-associated tumors.
Blessmann M; Gröbe A; Quaas A; Kaifi JT; Mistakidis G; Bernreuther C; Sauter G; Gros S; Rawnaq T; Friedrich R; Mautner VF; Smeets R; Heiland M; Schachner M; Izbicki JR
Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 Feb; 113(2):239-44. PubMed ID: 22677742
[TBL] [Abstract][Full Text] [Related]
32. Tumor suppressor mutations and growth factor signaling in the pathogenesis of NF1-associated peripheral nerve sheath tumors. I. The role of tumor suppressor mutations.
Carroll SL; Stonecypher MS
J Neuropathol Exp Neurol; 2004 Nov; 63(11):1115-23. PubMed ID: 15581179
[TBL] [Abstract][Full Text] [Related]
33. Whole-exome sequencing of breast cancer, malignant peripheral nerve sheath tumor and neurofibroma from a patient with neurofibromatosis type 1.
McPherson JR; Ong CK; Ng CC; Rajasegaran V; Heng HL; Yu WS; Tan BK; Madhukumar P; Teo MC; Ngeow J; Thike AA; Rozen SG; Tan PH; Lee AS; Teh BT; Yap YS
Cancer Med; 2015 Dec; 4(12):1871-8. PubMed ID: 26432421
[TBL] [Abstract][Full Text] [Related]
34. Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings.
Spurlock G; Knight SJ; Thomas N; Kiehl TR; Guha A; Upadhyaya M
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1869-80. PubMed ID: 20229272
[TBL] [Abstract][Full Text] [Related]
35. Vascular endothelial growth factor, basic fibroblast growth factor and epithelial growth factor receptor in peripheral nerve sheath tumors of neurofibromatosis type 1.
Friedrich RE; Beer C; Glatzel M; Hagel C
Anticancer Res; 2015 Jan; 35(1):137-44. PubMed ID: 25550544
[TBL] [Abstract][Full Text] [Related]
36. Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.
Mattox AK; Douville C; Silliman N; Ptak J; Dobbyn L; Schaefer J; Popoli M; Blair C; Judge K; Pollard K; Pratilas C; Blakeley J; Rodriguez F; Papadopoulos N; Belzberg A; Bettegowda C
Elife; 2022 Mar; 11():. PubMed ID: 35244537
[TBL] [Abstract][Full Text] [Related]
37. Reprogramming Captures the Genetic and Tumorigenic Properties of Neurofibromatosis Type 1 Plexiform Neurofibromas.
Carrió M; Mazuelas H; Richaud-Patin Y; Gel B; Terribas E; Rosas I; Jimenez-Delgado S; Biayna J; Vendredy L; Blanco I; Castellanos E; Lázaro C; Raya Á; Serra E
Stem Cell Reports; 2019 Feb; 12(2):411-426. PubMed ID: 30713041
[TBL] [Abstract][Full Text] [Related]
38. Modeling tumors of the peripheral nervous system associated with Neurofibromatosis type 1: Reprogramming plexiform neurofibroma cells.
Mazuelas H; Carrió M; Serra E
Stem Cell Res; 2020 Dec; 49():102068. PubMed ID: 33160273
[TBL] [Abstract][Full Text] [Related]
39. The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas.
Pemov A; Li H; Patidar R; Hansen NF; Sindiri S; Hartley SW; Wei JS; Elkahloun A; Chandrasekharappa SC; ; Boland JF; Bass S; ; Mullikin JC; Khan J; Widemann BC; Wallace MR; Stewart DR
Oncogene; 2017 Jun; 36(22):3168-3177. PubMed ID: 28068329
[TBL] [Abstract][Full Text] [Related]
40. Molecular Analysis of Hybrid Neurofibroma/Schwannoma Identifies Common Monosomy 22 and α-T-Catenin/CTNNA3 as a Novel Candidate Tumor Suppressor.
Stahn V; Nagel I; Fischer-Huchzermeyer S; Oyen F; Schneppenheim R; Gesk S; Bohring A; Chikobava L; Young P; Gess B; Werner M; Senner V; Harder A
Am J Pathol; 2016 Dec; 186(12):3285-3296. PubMed ID: 27765635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
